Sorafenib for the treatment of unresectable hepatocellular carcinoma.
about
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something NewHepatocellular carcinoma: Where are we?Targeting angiogenesis in gynecologic cancersRole of microRNAs in hepatocellular carcinoma: a clinical perspectiveHepatocellular Carcinoma: Therapeutic Guidelines and Medical TreatmentThe role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinomaSynergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cellsNew inhibitors of VEGFR-2 targeting the extracellular domain dimerization process.Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting.Quantitative perfusion- and diffusion-weighted magnetic resonance imaging of gastrointestinal cancers treated with multikinase inhibitors: a pilot study.A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF.MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches.Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axisSafety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B CirrhosisAnti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives.Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancerTargeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implicationsCryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinomaCryotherapy is associated with improved clinical outcomes of sorafenib for the treatment of advanced hepatocellular carcinoma.Advances in paediatric cancer treatmentSorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans.Potentiality and boundaries of use of sorafenib in patients with hepatocellular carcinoma: awaiting the results of ongoing clinical trials.Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group.Proteinase-activated receptor 2 (PAR2) in hepatic stellate cells - evidence for a role in hepatocellular carcinoma growth in vivoeNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignanciesThe role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical managementKnockdown of 14-3-3ζ enhances radiosensitivity and radio-induced apoptosis in CD133(+) liver cancer stem cells.Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells.Intra-arterial iodine-131-lipiodol for unresectable hepatocellular carcinoma.Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.Pigment epithelium-derived factor as an impending therapeutic agent against vascular epithelial growth factor-driven tumor-angiogenesis.Targeting integrins in hepatocellular carcinoma.Recent advances in anti-angiogenic therapy of cancerRole of stress-induced NKG2D ligands in liver diseases.Current concepts in pediatric liver tumors.
P2860
Q26744542-7B258D7E-5EA4-42A9-86AE-20699EA4A412Q26765182-C6BC6DE1-E91D-47E1-B98E-493479D34C29Q26824766-05316786-2C00-4A81-8E95-B0BF5674EDE4Q27014034-F556955A-0B84-4891-A88B-BFCC0A29B95CQ28079378-DDA9953E-7FD5-4427-B1F7-58CE3F933F5AQ28477884-89FCEEEE-3583-48CF-8719-2C3D541EB185Q28539940-3CE2CFAB-6593-4EA4-ACEF-E4F41E265A35Q34027266-77A82197-58AC-4593-B932-19B50CC9FC16Q34131801-4FF1A5D1-BF3E-448F-B0BA-FCC1491E9EC1Q34229404-5DCB7019-02CA-414F-AF71-D2C7A80BB4D2Q34402062-20B6E598-7D52-4A23-BE0E-7D4C6C38677BQ34675280-24B3503A-97D9-460F-81CB-BE87075E5BC8Q34758477-12624023-633D-4ACC-97D9-164D7F55932FQ35005616-B72BEAB9-4E6C-41D0-89F3-4261202A237CQ35030418-C3CD1DB9-A791-49B9-92BF-33F073EF4B29Q35205410-D3A9B0FD-B794-4638-A2EA-50EF96606710Q35626761-7F628984-43D2-4445-ADAF-6325724172F2Q35740123-454C54B6-C705-4CE3-9D40-470174C172EBQ35759606-8120734F-04AE-41D7-8068-77B7D8105EC3Q35963024-2A8D74EC-A006-4CC4-A2DB-E500EB757E74Q36224737-694A6159-7DE3-4036-B423-CDFD1D2D98F1Q36508630-D5A19A24-6B47-45FA-B89F-9F65DCC2420FQ36654402-E8C0C519-70A5-4E99-95FF-8903CE81FFD6Q36922232-9EFBB636-E86F-4208-BC5E-772E46926B25Q37017008-6E6447D6-28E1-4B49-899D-D8EF12875CF5Q37046852-A5BBB18E-629D-4FC9-9F5B-8DFDD9399063Q37138893-CE5A798A-0CF9-4974-85ED-27C6E898394AQ37317462-85DA5F4C-4DC7-4403-AD94-869F872D2E22Q37441525-61102DAB-5610-4F52-B7D2-0F3A0E53B6C6Q37595952-D4CB6F9F-B09A-47BC-977F-54066E870B73Q37621007-615E7B37-4043-4327-A862-1B06D22B615AQ37687133-8741FEB6-E340-4E44-9A9E-117E9FAF75A6Q37719254-DB70016D-0191-4D60-BCAD-97D8A56624FBQ37766533-977F37BD-D408-4BCD-A80A-3CC65F03B7E7Q37827878-E3CD0649-2CC2-4FEE-8AA7-D958B0F7800BQ37828119-7A6DD1C5-391D-4328-8BC6-D8E589651474Q37844564-CC67A5C7-760F-4568-AC57-A1221CB57560Q37852512-B8F17B80-7B66-42E3-AD64-CE214B3BE118Q37957971-79A1A30A-960D-4D24-9874-E933FDED0342Q38007187-858247F5-EF9C-41CC-AA0B-5110079B8AA5
P2860
Sorafenib for the treatment of unresectable hepatocellular carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sorafenib for the treatment of unresectable hepatocellular carcinoma.
@en
type
label
Sorafenib for the treatment of unresectable hepatocellular carcinoma.
@en
prefLabel
Sorafenib for the treatment of unresectable hepatocellular carcinoma.
@en
P2093
P1433
P1476
Sorafenib for the treatment of unresectable hepatocellular carcinoma.
@en
P2093
Ann T Farrell
Brian Booth
Rajanikanth Madabushi
Rajeshwari Sridhara
Richard Pazdur
Robert C Kane
Robert Justice
Somesh Chattopadhyay
P304
P356
10.1634/THEONCOLOGIST.2008-0185
P577
2009-01-14T00:00:00Z